Saturday 17 October 2026 Export PRVA’s income statement to Excel — free account

Privia Health Group, Inc.

PRVA Healthcare Health Information Services

Privia Health Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 22.3% from fiscal 2024. In the quarter to June 2026, revenue grew 21.4%, EPS grew 250.0% and free cash flow fell 86.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

22.46 0.16 −0.71%

Follow PRVA

Alert me

Market cap: $2.9B
P/E: 102×
Fwd P/E: 87.8×
Dividend yield: —
F-score: 6/9
Altman Z: 4.78
Beneish M: −2.59
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 22.24

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	2	—	2	8	1	4	3	4	—	—	—

Insider Ownership 5.92%

Capital & Financial Ratios $m

Market Cap 2,890.00

Revenue 2,358.07

Net Income 33.84

Free Cash Flow 131.13

Net Debt (412.20)

Current Ratio 1.62

Debt/Equity 0.00

P/E ratio 102.09

Fwd P/E 87.80

P/S ratio 1.20

P/B ratio 3.38

Past 5Y EPS Growth (10.99%)

This Y EPS Growth 43.08%

Next Y EPS Growth 61.99%

Next Y revenue growth 15.79%

Next 5Y EPS Growth 46.98%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 21.52%

10-year low 10-year high

P/S against its own 10 years 6.25%

10-year low 10-year high

P/B against its own 10 years 12.07%

10-year low 10-year high

EV/Sales against its own 10 years 9.96%

10-year low 10-year high

EV/FCF against its own 10 years 14.25%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	390	491	480	412
Receivables	291	316	401	574
Inventory	—	—	—	—
Other	—	—	—	—
	701	835	911	1,025

	2023	2024	2025	Q'26
Payables	58	82	97	91
ST’ Debt	—	—	—	—
Other	326	365	470	541
	387	449	569	634

Compound Annual Growth %

	10y	5y	3y
Sales	—	21.04%	16.10%
Cash Flow	—	33.25%	51.28%
Earnings	—	(6.01%)	0.00%
Book Value	—	40.66%	15.07%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	604	633	—	—	—
’25	480	521	580	541	2,123
’24	415	422	438	461	1,736
’23	386	413	417	441	1,658
’22	314	336	343	364	1,357
’21	214	226	252	275	966
’20	213	183	207	214	817

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(49)	1	—	—	—
’25	(24)	8	52	128	163
’24	(33)	34	33	75	109
’23	(13)	8	22	64	81
’22	(5)	7	16	29	47
’21	(2)	7	63	(12)	55
’20	(7)	14	36	(3)	39

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(49)	1	—	—	—
’25	(24)	8	52	128	163
’24	(33)	34	33	75	109
’23	(13)	8	22	64	81
’22	(5)	7	16	29	47
’21	(2)	7	62	(12)	55
’20	(7)	13	36	(3)	39

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.02	0.07	—	—	—
’25	0.03	0.02	0.05	0.07	0.18
’24	0.02	0.03	0.03	0.03	0.11
’23	0.06	0.06	0.05	0.02	0.19
’22	(0.16)	(0.10)	0.01	0.14	(0.08)
’21	0.06	(1.68)	(0.09)	(0.11)	(1.83)
’20	0.06	0.05	0.17	0.04	0.32

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	20.20	17.99	19.68	15.92	18.77	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	50.77	44.64	30.15	24.05	26.51
People
People	Employees	—	—	—	—	559	810	964	1,102	1,140	1,226
	Revenue/emp, $m	—	—	0.00	0.00	1.46	1.19	1.41	1.50	1.52	1.73
Income, $m
Income, $m	Revenue	—	—	658	786	817	966	1,357	1,658	1,736	2,123
	Gross margin, %	—	—	8.36	8.71	10.11	6.59	9.93	9.74	10.19	9.87
	EBT	—	—	(4)	9	23	(219)	(19)	29	28	44
	EBT margin, %	—	—	(0.61)	1.16	2.87	(22.61)	(1.37)	1.75	1.61	2.07
	Net income	—	0	(3)	8	31	(191)	(12)	21	17	30
	Depreciation	—	—	1	2	2	3	5	7	7	10
Per share, $
Per share, $	Revenue	—	—	6.21	8.20	8.52	9.39	12.26	14.20	14.54	17.38
	Earnings	—	—	(0.03)	0.08	0.32	(1.83)	(0.08)	0.20	0.12	0.19
	Cash flow	—	—	0.05	0.25	0.41	0.53	0.43	0.69	0.92	1.34
	Capex	—	—	0.00	(0.06)	0.00	(0.01)	0.00	0.00	0.00	0.00
	Free cash flow	—	—	0.05	0.19	0.40	0.53	0.43	0.69	0.92	1.34
	Book value	—	—	0.00	0.00	1.50	4.37	4.69	5.20	5.72	6.47
	Shares, m	—	—	106	96	96	103	111	117	119	122
Valuation, ×
Valuation, ×	P/E	—	—	70.42	70.42	70.42	0.00	0.00	124.79	150.38	131.72
	P/S	—	—	2.70	2.70	2.70	2.76	1.82	1.67	1.34	1.36
	P/B	—	—	14.78	14.78	14.78	5.92	4.75	4.56	3.42	3.66
	EV/Sales	—	—	2.64	2.64	2.64	2.46	1.59	1.45	1.08	1.15
	EV/FCF	—	—	50.05	50.05	50.05	43.56	45.67	29.94	17.20	15.01
Cash, $m
Cash, $m	Operating cash flow	—	—	5	24	39	55	47	81	109	163
	Capex	—	—	0	(6)	0	(1)	0	0	—	—
	Free cash flow	—	—	5	19	39	55	47	81	109	163
Balance, $m
Balance, $m	Working capital	—	—	—	14	43	256	288	314	386	342
	Total debt	—	—	—	40	33	32	8	—	—	—
	Net debt	—	—	—	(7)	(52)	(289)	(348)	(390)	(491)	(480)
	Shareholders’ equity	—	—	—	—	144	450	519	607	683	791
Returns, %
Returns, %	ROA	—	—	0.00	0.00	19.00	(37.08)	(1.16)	2.57	1.35	1.83
	ROIC	—	—	—	0.00	17.28	(84.26)	(6.99)	5.92	5.52	6.87
	ROE	—	—	0.00	6.42	24.61	(63.39)	(1.77)	4.10	2.23	3.11

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
DOCS Doximity, Inc.	$5.6B	34.8×	26.2×	+7.34% (above 0%: growing)	−53.57% (below 0%: shrinking)	−34.14% (below 0%: shrinking)	84.87%	21.48%	Compare
WAY Waystar Holding Corp.	$5.4B	38.0×	22.4×	+18.11% (above 0%: growing)	+10.53% (above 0%: growing)	−52.42% (below 0%: shrinking)	69.44%	23.79%	Compare
HTFL Heartflow, Inc.	$4.4B	— (loss-making)	— (loss-making)	+47.57% (above 0%: growing)	n/m	+62.62% (above 0%: growing)	83.00%	(27.93%)	Compare
PRVA Privia Health Group, Inc.	$2.9B	102×	87.8×	+21.39% (above 0%: growing)	+250.00% (above 0%: growing)	−86.20% (below 0%: shrinking)	9.93%	1.86%
SDGR Schrodinger, Inc.	$1.9B	— (loss-making)	— (loss-making)	+7.54% (above 0%: growing)	n/m	+34.43% (above 0%: growing)	55.07%	(70.55%)	Compare
OMCL Omnicell, Inc.	$1.6B	41.6×	55.1×	+7.45% (above 0%: growing)	+341.67% (above 0%: growing)	+107.90% (above 0%: growing)	48.98%	10.39%	Compare
CERT Certara, Inc.	$1.5B	— (loss-making)	— (loss-making)	+0.99% (above 0%: growing)	n/m	−78.46% (below 0%: shrinking)	62.34%	(0.21%)	Compare
GDRX GoodRx Holdings, Inc.	$1.2B	62.7×	30.9×	−1.31% (below 0%: shrinking)	−25.00% (below 0%: shrinking)	+112.45% (above 0%: growing)	89.52%	11.79%	Compare
OMDA Omada Health, Inc.	$1.1B	252×	143×	+43.12% (above 0%: growing)	n/m	+45.71% (above 0%: growing)	72.62%	4.04%	Compare
Median of peers	$1.8B	41.6×	30.9×	+7.49%	−7.23%	+40.07%	71.03%	7.22%

All 51 Health Information Services stocks →

Privia Health Group, Inc. (PRVA) key facts

Strength: Privia Health Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 22.3% from fiscal 2024.
Strength: Net income was $29.7 million, or $0.19 per share (basic), a net margin of 1.08%.
Privia Health Group, Inc. (PRVA) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PRVA traded at $22.46, a market capitalization of $2.9 billion.
At that price the stock trades at 102× trailing-twelve-month earnings and 1.2× sales; its P/E is higher than 22% of its own readings over the past ten years.
Return on equity was 3.11% and debt-to-equity 0.00.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 4.78 (safe zone) for fiscal 2025.